Refractory Malignant Solid Neoplasm: Clinical Trials

2 trials for Refractory Malignant Solid Neoplasm, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 suspended. 2 Phase 1, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 12Suspended 2
Phase 21Suspended 1

Follow Refractory Malignant Solid Neoplasm: new trials by email Literature Review of Refractory Malignant Solid Neoplasm trials Research Report on Refractory Malignant Solid Neoplasm

Trials (filtered) newest first · largest first

All 2 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Testing the Addition of an Anti-cancer Drug, DT2216, to the Usual Chemotherapy Treatment for Relapsed or Refractory Solid Tumors and Fibrolamellar Carcinoma
Bcl-XL Proteolysis Targeting Chimera DT2216, Biospecimen Collection, Irinotecan - Childhood Fibrolamellar Carcinoma, Recurrent Childhood Fibrolamellar Carcinoma
Phase 1 / Phase 2SuspendedChildren's Oncology Group812025-06-122026-08-24
AU409 for the Treatment of Advanced Primary Liver Cancers or Solid Tumor With Liver Metastatic Disease
Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging - Advanced Cholangiocarcinoma, Advanced Hepatocellular Carcinoma
Phase 1SuspendedUniversity of Southern California362023-03-292026-08-17

Narrower conditions

Carcinoma, Hepatocellular (1)  ·  Fibrolamellar hepatocellular carcinoma (1)

Broader conditions

Adenocarcinoma (1)  ·  Carcinoma (1)  ·  Digestive System Diseases (1)  ·  Digestive System Neoplasms (1)  ·  Liver Diseases (1)  ·  Liver Neoplasms (1)  ·  Neoplasms (1)  ·  Neoplasms by Histologic Type (1)  ·  Neoplasms by Site (1)  ·  Neoplasms, Glandular and Epithelial (1)

Interventions

Specimen Handling (2)  ·  DT2216 (1)  ·  Irinotecan (1)  ·  Magnetic Resonance Spectroscopy (1)

Sponsors

Children's Oncology Group (1)  ·  University of Southern California (1)

Countries

United States (2)

Top investigators

Anthony B El-Khoueiry, MD (1)  ·  Michael V Ortiz (1)

NIH funding

P30CA014089 (1), UM1CA228823 (1)